Introduction
N-terminal pro brain natriuretic peptide (NT-proBNP) is endorsed by international guidelines as a diagnostic test for acute decompensated heart failure (ADHF).
1,2 Underpinning data were generated from studies recruiting Caucasian patients in Western centres. 3 -5 among acutely symptomatic patients. 4, 5 However, test performance is influenced by the prevalence of the condition of interest as well as that of potential confounding co-morbidities which may differ between patients in the Asian and Western centres.
Factors known to influence test performance of NT-proBNP include age, renal function, AF, and obesity. 4 -11 It is not known whether ethnicity or interaction(s) between ethnicity and co-morbidities influence the test performance of NT-proBNP. East vs. West interethnic differences in plasma concentrations of NT-proBNP, cardiac structure, and function have been reported.
12 -14 Furthermore, the demography and clinical characteristics may differ between those attending Emergency Services in Asia compared with the West, and this in turn may influence test performance. Prospectively planned, contemporaneous comparisons of heart failure markers in Asian vs. Western settings are lacking. The current report compares the diagnostic test performance of NT-proBNP in Singapore and New Zealand (NZ), representing Asia and the West, respectively.
Methods
Patients were recruited contemporaneously according to identical criteria at the emergency departments (EDs) of the National University Hospital, Singapore and Christchurch Hospital, NZ. Both hospitals are tertiary facilities providing a comprehensive range of clinical services for populations of ∼1 000 000 for the Singapore centre and 500 000 for the NZ centre. Both centres have busy EDs, accommodating >110 000 and 60 000 attendances per annum, respectively. The study was approved by the institutional review boards of the two enrolling institutions.
Shortness of breath as the primary complaint triggering presentation to the ED was the key inclusion criterion. Age under 21 years, shortness of breath related to trauma, and current renal haemodialysis were exclusion criteria.
Adjudication
Two clinicians (an ED specialist and a cardiologist) independently reviewed all available information on each patient and attributed breathlessness to heart failure, pneumonia, or another cause. They were blinded to NT-proBNP measurements but could access medical records, case report forms, and other test results including cardiac imaging as available. In NZ, disagreement between the two adjudicators was resolved by consensus. In Singapore, a third adjudicator gave a final diagnosis. In the majority of cases in both countries, author A.M.R. participated in the blinded adjudication process to ensure matching assessment procedures across the two centres.
N-terminal pro brain natriuretic peptide assay
Venous blood was collected into EDTA tubes, separated, and the plasma was stored at -80 ∘ C pending assay. NT-proBNP was measured by electrochemiluminescent immunoassay on the Elecsys Cobas e411 Immunoanalyser (Roche Diagnostics). The measuring range of the assay was 5-35 000 pg/mL. 
Statistical analysis
Values are expressed as means and standard deviations, medians and quartiles, or counts and percentages as appropriate. Where appropriate, skewed data (as for plasma NT-proBNP) were normalized by log transformation. Univariate analyses were performed with Pearson's correlation, independent t-tests, one-way analysis of variance (ANOVA), 2 test, and Fisher's exact test as appropriate. Age, gender, estimated glomerular filtration rate (eGFR), AF, history of congestive heart failure, myocardial infarction, COPD, diabetes, examination variables [rales, wheezing, murmur, oedema, and elevated jugular venous pressure (JVP)], and chest X-ray findings were related to NT-proBNP (general linear model) and to the diagnosis of ADHF (logistic regression). Interaction analyses were performed to identify potential differences in (i) the relationship of age to NT-proBNP and (ii) the relationship of age to the diagnosis of ADHF between countries. Chest X-ray findings were scored, with one point allocated for the presence of each of increased cardiothoracic ratio, interstitial oedema, alveolar oedema, and pleural effusion.
The discriminative power of NT-proBNP for the diagnosis of ADHF was analysed separately for Singapore and NZ patients by receiver operating characteristic (ROC) curve analyses applied to each cohort in full and to subgroups stratified by age, renal function, body mass index (BMI), and presence or absence of diabetes and AF. Areas under the ROC curves (AUCs) were compared by the method of Hanley and McNeil. 15 Optimal single ROC-generated values of NT-proBNP for Singapore and NZ cohorts were derived from the points on ROCs at the point closest to perfect sensitivity and specificity. The sensitivity, specificity, positive predictive value (PPV), NPV, and accuracy of NT-proBNP were calculated for each full country cohort and the designated subgroups. P < 0.05 was taken to indicate significance.
Results
Between 2010 and 2013, a total of 606 patients were recruited in Singapore (45.4% Chinese, 29.7% Malay, 16.7% Indian, and 8.3% other) and 500 in NZ (92% Caucasian, 2.4% Maori, 0.8% Pacific Islander, and 4.8% other). Cohort characteristics are shown in Table 1 . Despite identical recruitment criteria, the two cohorts differed strikingly. Median age was 17 years older in NZ compared with Singapore, with concordantly reduced renal function and more frequent past history of CAD or congestive heart failure. NZ patients more frequently had AF, COPD, and severe symptoms. Diabetes was more prevalent among Singapore patients.
Adjudicated diagnosis of acute decompensated heart failure
A final adjudicated diagnosis of ADHF was more common in NZ than in Singapore (36 vs. 24%, P < 0.001). Table S1 in the Supplementary material online displays the characteristics of the 180 NZ and 148 Singapore patients with ADHF. Median plasma NT-proBNP was similar in the two ADHF groups [4234 (2008-9799 ) pg/mL and 4429 (2123-9479) pg/mL for Singapore and NZ, respectively (P = 0.37). NZ patients were older [median 78 (69-84) years vs. 61 (54-72) years; P < 0.001), had poorer renal function, and were twice as likely to be in AF compared with Singapore patients. Again, diabetes was more common in Singapore ADHF, acute decompensated heart failure; BMI, body mass index; CABG, coronary artery bypass grafting; CHF, congestive heart failure; CTR, cardiothoracic ratio; eGFR, estimated glomerular filtration rate; MI, myocardial infarction; PND, paroxysmal nocturnal dyspnoea; PTCA, percutaneous transluminal coronary angioplasty.
(54% vs. 24%; P < 0.001). Notably, the rate of frank pulmonary oedema present on X-ray was 26% in Singapore and 13% in NZ (P < 0.001).
Test performance
NT-proBNP discriminated ADHF better in Singapore than in NZ, with AUCs of 0.926 and 0.866, respectively (P = 0.012; Figure 1 Table 2 ). When non-Asian participants were removed from Singapore data and non-Caucasian participants from NZ data, the AUCs were little changed at 0.926 (0.905-0.948) and 0.870 (0.838-0.901), respectively. Optimal single ROC-derived diagnostic values of NT-proBNP for Singapore and NZ cohorts differed at 600 and 1350 pg/mL, respectively, with associated sensitivities of 94% and 87%, specificities of 82% and 75%, a PPV of 62% and 66%, an NPV of 98% and 91%, and accuracies of 85% and 79%. Table 3 compares test performance characteristics of the commonly accepted single NT-proBNP rule-out cut-off point (300 pg/mL) and age-adjusted values (450 pg/mL in those <50 years, 900 pg/mL for 50-75 years, and 1800 pg/mL for >75 years) 6 in subgroups stratified by age, renal function, BMI, and presence or absence of AF. Sensitivity and NPV are comparable, whereas specificity and accuracy are consistently and substantially better in the Singapore cohort compared with the NZ cohort.
The univariate and multivariate (independent) associates of plasma NT-proBNP and of the diagnosis of ADHF were investigated in both cohorts (Tables 4 and 5). variables independently associated with ADHF on multivariable analysis. Final panels of six and seven variables accounted for 64% and 56% (R 2 = 0.636 and 0.557) of interindividual variation in plasma NT-proBNP values in Singapore and NZ patients, respectively. In both countries, (i) a diagnosis of ADHF, (ii) renal function, and (iii) age ranked as the first, second, and third most powerful determinants of plasma NT-proBNP, with ADHF easily the most powerful associate in both cohorts. However, the ranking of factors beyond the top three differed between countries, with sex, BMI, and AF fourth to sixth in the sequence for Singapore (with all significant) in contrast to NZ where AF took the fourth position followed by a history of myocardial infarction, BMI, and sex (with none of the latter three variables remaining statistically significant).
Univariate comparisons of 50 demographic, clinical, and test variables indicated significant differences between ADHF and non-ADHF cases for 41 and 46 variables in Singapore and NZ, respectively (Supplementary material online, Tables S2-S4). Table 5 lists variables remaining independently associated with the diagnosis of ADHF after multivariable analysis for the two cohorts combined and separately for Singapore and NZ. In all three analyses, plasma NT-proBNP and chest X-ray score were the most powerful independent predictors of the diagnosis of ADHF, attaining Wald values in excess of 20 with associated P < 0.0001. Six further variables were independently significant within the analysis of all 1106 patients (Singapore and NZ patients combined) but these all have Wald values below 10. Of these six variables, three (BMI, rales, and oedema) remained significant when Singapore data were considered separately, and two different variables (orthopnoea and elevated JVP) remained significant in the analysis of NZ data ( Table 5) . Scatter plots of plasma NT-proBNP and age, renal function, and BMI ( Figure 2) for Singapore and NZ patients all closely overlapped with parallel or overlapping lines of regression and similar R values. There was no interaction between country (i.e. Singapore or NZ as surrogates for ethnicity) and the relationship of any variable including age with NT-proBNP or the diagnosis of ADHF. their NZ counterparts, less symptomatic, and carried a lower burden of co-morbidity, with the striking exception of diabetes. Clear differences in age, renal function, prevalence of AF, and diabetes persisted among those with a final adjudicated diagnosis of ADHF (Tables 1 and 2) . The similar median NT-proBNP in the two adjudicated ADHF subgroups contrasted with the clear and expected differences between the two breathless cohorts overall. Notably rates of frank pulmonary oedema were higher in Singapore than in NZ. This suggests the degree of decompensation at presentation was more severe in those with ADHF in Singapore and in turn this may reflect differences in delay to presentation and in access to services between countries. This will require further clarification in future international comparison studies. On this background, plasma NT-proBNP displayed superior diagnostic performance for discrimination of ADHF in Singapore compared with NZ. The internationally accepted rule-out and age-adjusted rule-in cut-off points of NT-proBNP all performed better in Singapore than in NZ. Application of the single cut-off point rule-out value of 300 pg/mL yielded comparable sensitivity and NPV in both countries but far better specificity (73% vs. results would correctly allocate patients to ADHF vs. non-ADHF categories 17 times more per 100 patients assessed in Singapore compared with NZ. Even though the use of the designated age-adjusted cut-off points improved results in both countries (with specificity improving to 86% and 71%, and accuracy to 86% and 77% in Singapore and NZ, respectively), the better performance in Singapore remained apparent. The performance of NT-proBNP was most clearly impaired in two subgroups, those with eGFR < 60 mL/min/1.73 m 2 and those with AF. In these two groups, the performance of NT-proBNP was similarly poor in both countries (Tables 2 and 3) . In contrast, in young patients (<50 years), the elderly (>75 years), patients with eGFR > 60 mL/min/1.73 m 2 , those with normal sinus rhythm, and regardless of weight and diabetes status, the better performance of NT-proBNP in Singapore was sustained.
Discussion
Notably, the relationships of plasma NT-proBNP to age, renal function, and BMI were consistent with previous reports and fell on the same lines of regression in both countries (Figure 2) . 4 -11 There was no interaction between country (i.e. Singapore or NZ as surrogates for ethnicity) and the relationship of any variable with NT-proBNP. These findings indicate that shifts in NT-proBNP concurrent with changes in these three key potential confounders are not affected by nationality or ethnicity. This suggests that the difference in test performance between countries reflects lower age, better renal function, and less frequent AF rather than any inherent inter-centre difference in the slope of age to marker or age/marker to diagnosis relationships. Multivariable analyses confirmed (i) the diagnosis of ADHF, (ii) renal function, and (iii) age, in that order, as the leading determinants of NT-proBNP in both countries (Table 4) , with AF next in line in NZ but lower in the rankings in Singapore. Together these findings indicate that the superior performance of NT-proBNP in Singapore was driven primarily by the younger age, better renal function, and lower prevalence of AF rather than any ethnic difference. The lesser presence of these key confounders also underlies the more powerful independent association between NT-proBNP and the diagnosis of ADHF seen in Singapore compared with NZ ( Table 5) .
In view of the younger age of patients presenting with ADHF throughout Asia compared with the Western experience, the superior performance of NT-proBNP seen in Singapore compared with NZ may be applicable to most of Asia.
16
Limitations of this report centre on the degree to which the Singapore cohort can be considered representative of Singapore and of Asia, and similarly the extent to which the NZ cohort is representative of NZ and of the 'West' in general. Both institutions are the main facility in their respective areas for admission and initial diagnosis of acutely breathless patients including the subgroup with ADHF. The Singapore centre receives acute cases from a population of ∼1 million out of Singapore's total population of ∼5.5 million. The NZ centre provides tertiary care for ∼500 000 of the 1 million population of the South Island of New Zealand. Both institutions provide a similar comprehensive range of clinical services. In both countries, the overwhelming majority (>95%) of severely breathless and ADHF cases will be attended to in the public hospitals. Furthermore, experience from recent recruitment of ADHF cohorts from all six major centres in Singapore contemporaneously with recruitment from the four largest hospitals in NZ indicates that the ages of the ADHF patients reported here are representative for each country (unpublished data). It is likely that the two cohorts reported here are truly representative of acutely breathless patients and their ADHF subgroups within their respective countries.
Data gathered from the ADHERE registry and other reports suggest that the average age of presentation in China and other Asian nations is even younger than recorded in Singapore. ADHF in Asia compared with the West lies outside the scope of this report, but is obviously of great concern and will continue to warrant close study and interventional initiatives throughout the region. The far higher prevalence of diabetes in the Asian cohort is likely to be relevant. The epidemiology of acute and chronic heart failure in NZ is very similar to that observed in Western Europe and the USA.
17 -19 Therefore, our findings may offer a true indication of more widespread distinctions between Asia and the West with respect to the epidemiology of heart failure. The superior performance of NT-proBNP documented in Singapore compared with NZ points to a similar test advantage in wider Asia.
In summary, considering emerging evidence of a markedly lower average age of presentation with ADHF over most of Asia compared with Western countries, our data suggest that NT-proBNP is likely to be more accurate when applied in Asian centres than in the West.
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Additional Supporting Information may be found in the online version of this article: Table S1 . Clinical characteristics of patients with final adjudicated diagnosis of ADHF. Table S2 . Univariate characteristics of all patients with final adjudicated diagnosis of ADHF (n = 1106). Table S3 . Univariate characteristics of NZ patients with final adjudicated diagnosis of ADHF (n = 500). Table S4 . Univariate characteristics of Singapore patients with final adjudicated diagnosis of ADHF (n = 606).
